Sign in
Taking peoplePhase 4

Two iron pills compared in women with iron deficiency anemia

Compares Sucrosomial® Iron with Ferric Maltol in women with iron deficiency anemia.

Key facts

Who runs it
Pharmanutra S.p.a.
Where
Spain6 sites in 1 countryChoose a country to see its sites
Registry title
Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women
Status
Recruiting
Phase
Phase 4
People taking part
146 people, planned
Started
11 Dec 2025
Planned end
Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sucrosomial® Iron (Sideral® Forte)
  • Ferric Maltol (Feraccru®)
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women with mild to moderate iron deficiency anemia. It compares two iron capsules taken by mouth for 12 weeks.

Age
18 years and older
Sex
Women only
Disease stage
Mild anemia (11.0 ≤ Hb < 12 g/dL) or moderate anemia (8.0 < Hb < 11 g/dL). Hb is hemoglobin, the oxygen-carrying part of blood.
Earlier treatment
No iron medicines or supplements within 1 month before screening. No erythropoietin within 3 months before screening. No previous weight-loss (bariatric) surgery.
Biomarker or test result
Hemoglobin (Hb) level between the limits above.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Need for a blood transfusion or iron given into a vein
  • Active cancer (fibroids and polyps are allowed)
  • Severe active inflammatory bowel disease, iron overload or inherited anemias such as thalassemia
  • Alcohol abuse or known allergy to the study product ingredients

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Female participants ≥ 18 years
  • Mild anemia (11.0 ≤ Hb < 12 g/dL) or moderate anemia (8.0 < Hb < 11 g/dL)
  • Signed informed consent

Who cannot take part

  • Use of iron-containing drugs or supplements within 1 month prior to screening
  • Use of erythropoietin within 3 months prior to screening
  • Previous bariatric surgery
  • Psychiatric disorders interfering with consent or compliance
  • Active cancer (except fibroids and polyps)
  • History of poor adherence or inability to comply
  • Hemochromatosis or iron overload syndromes
  • Known hypersensitivity to study product ingredients
  • Pregnant or breastfeeding women
  • Participation in another interventional study
  • Need for blood transfusion or IV iron (per investigator judgment)
  • Severe active IBD (HBI > 16 for Crohn; CAI > 12 for ulcerative colitis)
  • Alcohol abuse
  • Hereditary anemias (including thalassemia)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare two oral iron treatments, Sucrosomial® Iron and Ferric Maltol, in women with mild to moderate iron deficiency anemia. Many patients experience gastrointestinal side effects or poor tolerability with traditional iron supplements, which may limit adherence. Participants will be randomly assigned to receive either Sucrosomial® Iron or Ferric Maltol for 12 weeks. The primary objective is to determine whether Sucrosomial® Iron is as effective as Ferric Maltol in normalizing hemoglobin levels.

The 2 groups in the trial

  • Sucrosomial® IronTreatment being tested

    Participants will receive dietary supplement Sucrosomial® Iron (Sideral® Forte) for 12 weeks. The dose consists of 60 mg/day of elemental iron (two capsules of Sideral® Forte per day), taken orally on an empty stomach (1 hour before or 2 hours after meals).

    Treatment: Sucrosomial® Iron (Sideral® Forte)

  • Ferric MaltolExisting treatment, for comparison

    Participants in this arm will receive Ferric Maltol (Feraccru®) for 12 weeks. The dose consists of 60 mg/day of ferric maltol (two capsules of Feraccru® per day), taken orally on an empty stomach (1 hour before or 2 hours after meals).

    Treatment: Ferric Maltol (Feraccru®)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women
Plain-language title
Two iron pills compared in women with iron deficiency anemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
3 September 2026